News

Search:
 Search

Latest News | 24 May 2012

Advisory Committee Votes Against Label Expansion for J&J/Bayer's Xarelto

0 Likes

The US Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee voted against Johnson & Johnson and Bayer’s co-developed oral anticoagulant drug Xarelto (rivaroxaban), Read More...


RF Today is Regulatory Focus' daily news brief. Each edition contains the top global regulatory news stories about pharmaceuticals, medical devices, biotechnology and more. Learn more

New Regulatory Focus Apps for iPad and iPhone